Showing posts with label Acute Treatment of Migraine. Show all posts
Showing posts with label Acute Treatment of Migraine. Show all posts
Monday, March 11, 2024

FDA Approves Zavzpret (zavegepant) Nasal Spray for the Acute Treatment of Migraine

›
Pfizer Inc. (NYSE: PFE)  announced the U.S. Food and Drug Administration (FDA)  approval of Zavzpret (zavegepant), the first and only calcit...
Tuesday, January 4, 2022

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 (meloxicam-rizatriptan) for the Acute Treatment of Migraine

›
  In continuation of my update on meloxicam,  Axsome Therapeutics, Inc.   that the U.S. Food and Drug Administration (FDA) has accepted for ...
Wednesday, December 1, 2021

FDA Approves Trudhesa (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

›
Impel NeuroPharma, Inc. (NASDAQ: IMPL),  announced  the U.S. Food and Drug Administration (FDA) approval of    Trudhesa ™ (dihydroergotamine...
Thursday, February 13, 2020

FDA Approves Ubrelvy (ubrogepant) for the Acute Treatment of Migraine

›
In continuation of my update on  Ubrelvy (ubrogepant) Allergan plc (NYSE: AGN),  announced that the U.S. Food and Drug Adminis...
Tuesday, February 12, 2019

FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine

›
In continuation of my update on  Tosymra (sumatriptan) Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today ann...